Endurance RP Limited provided updates on the PE prevention drug - Fortacin /Senstend (the marketing name of Fortacin in China). Regarding the clinical study for seeking approval of an import licence for Senstend™  from the National Medical Products Administration of The People's Republic of China ("China"), among the three drug trials that Wanbang Biopharmaceutical Co. Ltd. (Wanbang Biopharmaceutical), the Company's commercial strategic partner for China and a wholly controlled company of Shanghai Fosun Pharmaceutical (Group) Co.

Ltd. registered in December 2021 with the Centre of Drug Evaluation, the two Phase 1 studies have been successfully completed and the remaining Phase 3 study remains ongoing. Despite certain COVID-19 lockdowns and restrictions being experienced in China, the Phase 3 study has commenced with 177 patients having signed informed consent forms to enter the study (approximately 62% complete) and 88 subjects having been randomised into the study (approximately 31% complete) as of 1 July 2022. Wanbang Biopharmaceutical has advised the Company that even with the aforementioned COVID-19 lockdowns and restrictions, enrolment and randomisation is estimated to complete in November 2022. The preparatory phase for preparing the New Drug Application ("NDA") to NMPA have been commenced with the aim of submitting the NDA by the end of Second Quarter 2023.

All costs of the clinical trials, including all other associated regulatory and submission costs are being met by Wanbang Biopharmaceutical. If the clinical study meets its endpoints and the NMPA grants an import licence for Senstend, USD 5 million (or approximately HKD 39 million before deduction of PRC withholding tax) will be payable to the Group from Wanbang Biopharmaceutical. In addition, upon first commercial sale of Senstend in China, USD 2 million (or approximately HKD 15.60 million before deduction of PRC withholding tax) shall be payable to the Group from Wanbang Biopharmaceutical.